Statements (123)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:awards |
gptkb:Forbes_Global_2000
gptkb:Fortune_India_500 |
| gptkbp:CEO |
gptkb:Umang_Vohra
|
| gptkbp:chairman |
gptkb:Yusuf_Hamied
|
| gptkbp:competitor |
gptkb:Aurobindo_Pharma
gptkb:Dr._Reddy's_Laboratories gptkb:Sun_Pharma gptkb:Glenmark_Pharmaceuticals gptkb:Lupin_Limited |
| gptkbp:country |
gptkb:India
|
| gptkbp:focusArea |
gptkb:diabetes
gptkb:allergy immunology oncology paediatrics women's health critical care dermatology gastroenterology nephrology ophthalmology pain management urology anti-inflammatory cardiovascular respiratory anti-infectives anti-bacterial antiretrovirals CNS (central nervous system) anti-allergics anti-asthmatics anti-coagulants anti-depressants anti-diabetics anti-diarrheals anti-emetics anti-epileptics anti-fungals anti-histamines anti-hypertensives anti-malarials anti-platelets anti-psychotics anti-rheumatics anti-spasmodics anti-ulcerants anti-virals anti-allergic anti-cancer anti-diabetic anti-fungal anti-hypertensive anti-obesity anti-parasitic anti-platelet anti-viral anti-smoking anti-asthmatic anti-addiction anti-anaemic anti-anaemics anti-bacterials anti-coagulant anti-constipation anti-depressant anti-diarrheal anti-emetic anti-epileptic anti-histaminic anti-migraine anti-osteoporosis anti-parasitics anti-psychotic anti-pyretic anti-pyretics anti-rheumatic anti-spasmodic anti-thyroid anti-tuberculosis anti-tussive anti-tussives anti-ulcerant vitamins and nutritionals |
| gptkbp:foundedBy |
gptkb:Khwaja_Abdul_Hamied
|
| gptkbp:foundedYear |
1935
|
| gptkbp:headquartersLocation |
gptkb:Mumbai
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cipla Limited
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
INE059A01026
|
| gptkbp:listedOn |
gptkb:NSE
BSE |
| gptkbp:logo |
Cipla_logo.svg
|
| gptkbp:manufacturingFacilities |
gptkb:Algeria
gptkb:Bangladesh gptkb:Brazil gptkb:China gptkb:Europe gptkb:India gptkb:Morocco gptkb:South_Africa gptkb:Uganda gptkb:United_States |
| gptkbp:market |
global
|
| gptkbp:notableFor |
affordable HIV/AIDS drugs
|
| gptkbp:numberOfEmployees |
over 25,000
|
| gptkbp:parentCompany |
gptkb:Cipla_Group
|
| gptkbp:products |
over-the-counter drugs
active pharmaceutical ingredients generic medicines |
| gptkbp:revenue |
INR 21,763 crore (FY 2022-23)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:NSE
BSE |
| gptkbp:stockSymbol |
gptkb:CIPLA
500087 |
| gptkbp:subsidiary |
gptkb:Cipla_Medpro
gptkb:Cipla_USA_Inc. |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.cipla.com/
|
| gptkbp:bfsParent |
gptkb:Cipla
|
| gptkbp:bfsLayer |
6
|